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1. Introduction
Professor Bailey has written an important and interesting paper in which experimental
designs for dose escalation are developed, improved and illuminated by her understanding
and experience of the properties of block designs (see [BaileyBailey2008]). Given the clarity of
her exposition I have few specific comments.
2. Caution in First Application of a Higher Dose
The interpretation of dose escalation studies as block designs assumes that individual cohorts
are homogeneous. Even if they are, the Te Genero trial shows the perils that can occur for the
first cohort. Recommendation 7.5.3 of [Senn, Amin, Bailey, Bird, Bogacka, Colman, Garrett, Grieve, and LachmannSenn
suggests that simultaneous treatment of all subjects is inappropriate. Should a similar
recommendation be made for the new dose in each cohort, not just the first, in case a tolerance
threshold is suddenly crossed?
3. Classes of Design: quadratic trend in the response
The general method of development of designs in the paper is to move from principles of design
to assessment using tools from optimum design theory. However, the comparisons can only be
over the class of designs considered. Are there designs not in this class that have slightly higher
values of, perhaps, the A-optimum criterion mentioned in Professor Bailey’s §6? If such designs
exist, are they only slightly more efficient than the designs found here?
As one example, in the customary approach to block designs the treatment effects τi are
arbitrary constants. But, with ordered doses there may be a smooth change of response. Is it
worthwhile modelling this, for some of the larger designs of Figure 3, as a polynomial trend?
The effect on the design may be appreciable; for a single cohort the optimum design for a
quadratic model allocates equal numbers of subjects to the minimum, maximum and central
dose, or across the two central doses if the number of doses is even.
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24. D-optimum Design for Quadratic Trend
I assume that the dose levels are equally spaced levels of a single factor x. Equally spaced
intervals in logdose are another possibility although scaling of the placebo then needs special
attention. The model for the expected response of a subject in cohort k who gets dose
xi is µk + β1xi + β2x
2
i
. I take the conditions (i) of Figure 3, corresponding to the last
designs in Table I. With the standard design there are ten cohorts and up to 11 dose
levels, so that k = 1, . . . , 10; in all there are 12 parameters. Since I am interested in
parametric curves, I used D-optimality which minimises the volume of confidence regions for
parameter estimates. When, as here, the cohort sizes are fixed the D-optimum design for all
parameters is the same as the Ds-optimum design for the parameters of interest β1 and β2
([Atkinson, Donev, and TobiasAtkinson et al.2007, p. 206]).
The algorithm used to find the optimum design is a simple modification of sequential design
construction ([Atkinson, Donev, and TobiasAtkinson et al.2007, §11.2]). The resulting design
for 200 subjects is in my Table I. The important feature is that the Ds-efficiency of the design
in Figure 3 relative to this design is 60.05%. The two designs have some features in common.
Both put about half the subjects in any cohort on the highest dose. One important difference
is that this new design allocates many more patients to placebo - 82 as opposed to 27; another
is the allocation of several subjects to central doses for the later cohorts as is to be expected.
Table I. A D-optimum design for a 10 cohort design when the dose response is quadratic. The relative
Ds-efficiency of Design (i) of Figure 3 is 60.05%
(i) n = 10,m = 20
Dose 0 1 2 3 4 5 6 7 8 9 10
Cohort 1 10 10 0 0 0 0 0 0 0 0 0
Cohort 2 10 0 10 0 0 0 0 0 0 0 0
Cohort 3 10 0 0 10 0 0 0 0 0 0 0
Cohort 4 10 0 0 0 10 0 0 0 0 0 0
Cohort 5 10 0 0 0 0 10 0 0 0 0 0
Cohort 6 10 0 0 0 0 0 10 0 0 0 0
Cohort 7 9 0 0 0 1 1 0 9 0 0 0
Cohort 8 8 0 0 0 4 0 0 0 8 0 0
Cohort 9 5 0 0 3 3 0 0 0 0 9 0
Cohort 10 0 0 0 10 0 0 0 0 0 0 10
(200 subjects)
5. Compound Designs
A desirable feature of the designs of Figure 3, perhaps due to the ‘Diversity Principle’,
is that the truncated designs from early stopping are close to the recommended design
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3for a smaller number of cohorts. This property is unlikely to hold for designs such
as that in my table. Other criteria of optimality might give designs with better
properties in this respect. It is however not necessary to choose between such criteria;
compound criteria can be used in which a weighted product of efficiencies is maximized
([Atkinson, Donev, and TobiasAtkinson et al.2007, cap. 21]). The purpose, as in Professor
Bailey’s §9, is to find designs that perform well for a variety of criteria.
6. The Halving Principle
The construction of the new designs in Professor Bailey’s Sections 3 and 7 by the use of a few
straightforward principles is appealing and should encourage their use. However, the design
in my table is such that slightly less than half of the subjects in cohort k receive dose k for
k = 7, 8 and 9. I think this design would be excluded by the ‘Halving Principle’. Were such
designs explored?
7. Designs for Categorized Responses
The design problem is made more general and simpler to solve by considering quantitative
responses, when the designs do not depend on the values of the parameters of the linear
model, in my case µk, β1 and β2. A difficulty for designs for categorical response, such as those
considered by [Zhang, Sargent, and MandrekarZhang et al.2006], is that the designs depend
on the unknown parameters of the logistic models used to categorise the response variables.
However, if the effects being explored are small, the results of [CoxCox1988] indicate that
designs for normal theory linear models are likely to be efficient. In any application numerical
exploration will be needed to determine the region over which designs for continuous response
have adequate efficiency.
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